Adaptive Biotechnologies (ADPT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $46.4 million, up 22% year-over-year, driven by 52% MRD segment growth and regulatory milestone revenue.

• Net loss narrowed to $32.1 million from $50.3 million in Q3 2023, with Adjusted EBITDA loss improving to $14.3 million from $29.8 million.

• Operating expenses decreased 11% year-over-year to $79.1 million, reflecting disciplined cost management and restructuring activities.

• Cash, cash equivalents, and marketable securities totaled $267.2 million as of September 30, 2024, supporting ongoing operations and strategic initiatives.

• Clinical and pharma segments benefited from regulatory milestones, expanded Medicare coverage, and increased MRD adoption.

Financial highlights

• MRD revenue was $37.5 million, up 52% year-over-year; Immune Medicine revenue was $9.0 million, down 32% year-over-year.

• clonoSEQ test volume increased 30% year-over-year to 19,600 tests; U.S. ASP grew 3% despite a $1.8 million reserve charge.

• Gross margin improved to 64%, with sequencing gross margin up 13 percentage points year-over-year.

• Adjusted EBITDA loss reduced to $14.3 million from $29.8 million in Q3 2023.

• Cost of revenue as a percentage of revenue decreased to 36% from 51% in Q3 2023.

Outlook and guidance

• Full-year MRD revenue guidance raised to $143–$145 million, up from previous $140–$145 million.

• Full-year operating expenses (excluding one-time items) expected at $335–$340 million, down from $340–$350 million.

• Annual cash burn target reduced to $105 million, a 31% reduction from 2023.

• ASP for clonoSEQ expected to average $1,300 per test in 2025, up $250 from 2023.

• NovaSeq launch planned for Q3 2025, expected to improve margin profile by 5–8% in the first year.